.png)
TARGET
Facilitate Med Tec Innovation
WE INCUBATE INNOVATION
&
PROVIDE ORIENTATION
The TARGET MedTec team provides strategic expertise and funds
for start ups to support the development and commercialization of
novel medical technologies and devices.
​
The TARGET team leverages its extensive expertise and relationships with competent authorities,
notified bodies, medical technology companies
to support the identification and facilitates commercialization of innovative devices.
It catalyses the transformation process
into new companies with exceptional entrepreneurial outcome.
HOW WE WORK
Evidence based - Industry experienced - Milestone focused
TARGET starts the process with a deep dive into the innovative technology followed by a business concept stress test. The valuation based on this information is our starting point to support the development of a value oriented milestone plan.
​
Expectations are jointly discussed and adjusted.
Individual funding strategies will be directly matched with the stepwise roadmap.
Investors are enabled to decide how to allocate funds
having a clear understanding of the technology related opportunities and how to mitigate risks.
​
​
THE MANAGEMENT TEAM
Target MedTec management team is passionate about a milestone approach based on over 70 man years of collective experience working with medical innovation in universities, global institutions and leading companies. medical innovation is more than creating an important solution to an unmet therapeutic or diagnostic need. It requires understanding of the full medical technology innovation and commercialization process.
​
Sharing leadership with an experienced team as early as possible makes the difference.
EDUARD KASPER
Chief Executive Officer​
Eduard is a experienced executive with more than 20 years of industry experience in medical technology, including a decade in international management positions.
Eduard has been a General Manager EMEA of MicroPort Vascular Therapies and EP Technology business. Before that he has held the position as an Area Director at Covidien-Medtronic, where he has been responsible for the Renal Denervation business in Europe.
Additionally, between 1994 and 2012 he held positions at STENTYS, Johnson & Johnson, Guidant-Abbott, Boston Scientific, Stryker and 3M in several commercialization roles.
Eduard received a Bachelor´s Degree in Business Economy and holds a Master of Business Administration from University of Applied Sciences in Augsburg and Munich.
GIANCARLO FASULO
Partner - International Business and Strategy
Giancarlo is a senior executive with more than 30 years of health care market experience in medical technology, including several roles covered in international management positions.
He has been a Vice President Neurovascular EMEA of Covidien/Medtronic Vascular Therapies. Before that he covered key role as Regional Director Southern Europe of EV3/Covidien. In addition he has been Country Managing Director Italy EV3 for a decade from 2003 till 2013.
Additionally, between 1991 and 2003 he held positions at 3M and Becton Dickinson (BD) covering different franchise experience in Diagnostic, Anesthesiology and Medical Supply always as business country leader.
Giancarlo received a Bachelor´s Degree in Business Economy at Catholic Milan University and holds a Master of Business in Communication at University Bocconi in Milan.
NORBERT WEGERER
Partner - Innovation and Technology
Norbert is a healthcare expert with more than 20 years of experience in the fields of medical devices. He worked for global players like Johnson & Johnson, Siemens and Stryker in crucial management positions with P&I responsibility in sales, marketing and administration. Throughout his career he built, formed and led teams on an international level dealing with complex medical products.
Additionally, Norbert is well connected within the European Union as a medical institution. The EU relies on his experience and consulting within the innovation project Horizon2020. Furthermore, as business coach, Norbert works closely together with Switzerland Global Enterprise.
As graduated engineer with diploma from University of Applied Sciences in Heidelberg, Norbert has a strong technical understanding.
THE STAKEHOLDERS
The driving force to bring innovation to the patients
THE STARTUP
Innovators
Translating clinical research results and medical technology innovation into a sustainable company is a complex and exhausting process.
Experienced clinicians and engineers, often don’t appreciate the importance of the many factors involved—most medical startups fail to commercialize their product and many promising concepts
and evident solutions never reach patients.
Emerging companies in other sectors face technical and market risks, but medical innovation includes the barriers of regulatory approval, reimbursement, clinical trials, and a complex sales channel strategy.
It is crucial to find the most efficient way through this labyrinth.
SERVICES
Solution-oriented services to cut time, cost and ... let you sleep at night
MILESTONES
Strategic Workflow
Every medical device startup must build a roadmap to create value and reduce risk. It highlights the most common factors for success and helps to further develop a successful milestone related business plan.​
Each of these Milestones are important to understand and they represent where investors risk adapt startup valuations to protect their investments.
BUSINESS PLAN
Allocate Capital to your Milestones
The business plan’s pro forma model should define investment amount and timing linked to the milestones described in the roadmap. Careful structuring in funding tranches around valuation inflection points majorly impacts risk reduction in future financing strategy.
An equity investor expects a realistic but at the same time ambitious concept. We support information about the target return of an investor before submitting your plan.
Equity investors don't know when they will be able to sell their shares. As a result a key consideration will be the exit. An exit plan and horizon must be considered.
COMMERCIALISATION
APPROVAL & REIMBURSEMENT
Executive Consulting & Operational Orientation
A successful reimbursement strategy is one of the most crucial steps a manufacturer makes in determining how to commercialize an innovative device. Having a comprehensive authority approval and reimbursement strategy early in the device’s development will translate the "theoretical availability for use" to an actually used status, meaning used on a daily basis by patients who can most benefit from it. We communicate with more than 400 hospitals and understand the European landscape of reimbursement processes. This enables you to achieve your goals within forecasted timelines.
​
CONTACT
Please send an Email and get in touch with our team. You may ask to complete the SES questionnaire for a first evaluation about where you stand with your invention related to the innovative potential and your team/business settings.
EUROPE Office Medical Valley Center, Erlangen, Germany
Call Erlangen, Germany +49 9181 5120260